

1. Describe the drug-receptor complex formation and comment on how down-regulation and up-regulation can impact your calculation of anesthetic drug dosages.


**Receptors** are macromolecules that operate on the cell surface membrane or in the cytoplasm and are involved in chemical signaling both inside and between cells (Farinde, 2023).

Drug action **receptors** can be categorized based on their location. The lipid bilayer of cell membranes contains many of the receptors believed to be most important for anesthetic activity. Examples of drugs that interact with membrane-bound receptors include opioids, benzodiazepines,  $\beta$ -blockers, catecholamines, intravenous sedative hypnotics, and muscle relaxants, the majority of which are antagonists. Intracellular proteins make up some receptors. Drugs that interact with intracellular proteins include theophylline, insulin, caffeine, steroids, and milrinone (Flood et al., 2022).


An **agonist** is a medication that binds to a receptor to activate it. The majority of agonists are reversible because they bind using a mix of hydrogen and ionic bonds. In rare cases, an agonist will form an irreversible covalent bond with the receptor. Proteins that are either bound or unbound to the agonist ligand are frequently thought of as receptors. The drug's impact is generated when the receptor binds to the agonist ligand. There is no action if the receptor is not bound. It is believed that the receptor state is binary: either it is bound or unbound, which results in different conformations. According to this theory, the total number of bound receptors is reflected in the strength of the drug's action. According to this perspective, the "most" drug action happens when all of the receptors are bound (Flood et al., 2022).

Also, drugs that attach to receptors without activating them are known as **antagonists**. Antagonists usually bind reversibly through hydrogen, ionic, and van der Waals interactions. Simply by blocking the agonist's ability to attach to the receptor and produce the desired pharmacological effect, antagonists stop agonists from working. When the response to the agonist is gradually inhibited by increasing quantities of the antagonist, this is known as competitive antagonism (Flood et al., 2022).

**Up-regulation (super sensitivity)**, is a cellular mechanism of increased response, and **down-regulation (desensitization)**, is cellular mechanism of decreased response (El-Fakahany & Merkey).



[112.png](#)



[113.png](#)

In other words, prolonged exposure to an **antagonist** usually results in **upregulation**, or the number of receptors increasing, whereas prolonged exposure to an **agonist** results in **downregulation**, or the number of receptors decreasing. For example,

chronic insulin exposure causes the insulin receptor to become downregulated. Increased hormonal binding causes receptor internalization and degradation, which progressively reduces the amount of insulin surface receptors (Marino et al., 2023). Upregulation and downregulation can be used to explain a number of medication dosing-related difficulties. For better understanding, long-term opioid use is often associated with **tolerance** to the drug, a condition in which the effects seem to wear off. The intracellular protein known as arrestins is produced in response to the activation of opioid receptors. Inducing receptor endocytosis and blocking G-protein signaling, arrestins attach to the intracellular region of the opioid receptor. Less "signaling" or tolerance is the outcome of this. One of the numerous processes that result in opioid tolerance is the activity of arrestins, which cause receptor down-regulation (Marino, Jamal & Zito, 2023).

Cell membrane receptor numbers are dynamic and respond to certain stimuli by either increasing (**upregulating**) or decreasing (**downregulating**). A patient with pheochromocytoma, for instance, has too many catecholamines in their blood. In reaction, the quantity of  $\beta$ -adrenergic receptors in cell membranes decreases in an effort to preserve equilibrium. By decreasing  $\beta$ -adrenergic receptors, long-term  $\beta$ -agonist treatment of asthma can also develop tachyphylaxis, which is a decreased response to the same dose of  $\beta$ -agonist that is frequently indistinguishable from tolerance. An increased response to succinylcholine, on the other hand, results from damage to lower motor neurons, which increases the number of nicotinic acetylcholine receptors in the neuromuscular junction. One of the numerous factors that contribute to variability in response to stimuli is the fluctuation of receptor numbers (Flood et al., 2022). **In summary**, tolerance refers to a gradual decreased response to a drug, requiring a higher dose of drug to achieve the same initial response.

## References:

El-Fakahany, E., & Merky, B. (Eds). *16 Receptor regulation-principles of pharmacology*.  
<https://open.lib.umn.edu/pharmacology/chapter/re...>

Farinde, A. (2023). *Drug-receptor interactions*. Merck manuals.  
[https://www.merckmanuals.com/.../PharmacodynamicsDrug-Receptor InteractionsMerck Manuals](https://www.merckmanuals.com/.../PharmacodynamicsDrug-Receptor%20InteractionsMerckManuals)

Flood, P., Shafer, S.L. (2022). Basic principles of pharmacology. In P. Flood & J. P. Rathmell & R. D. Urman (Eds.), *Stoelting's pharmacology & physiology in anesthetic practice* (6th ed.). Wolters Kluwer.

<https://nursehowie.net/uploads/2023/01/Stoelt...>

Marino, M., Jamal, Z., & Zito, P.M. (2024). *Pharmacodynamics*. In: StatPearls Publishing.  
<https://www.ncbi.nlm.nih.gov/books/NBK507791/>